Resmetirom: A New Era in MASH Care
Metabolic dysfunction-associated steatohepatitis (MASH) is an underdiagnosed, often asymptomatic disease that is expected to increase in prevalence with the growing rates of metabolic syndrome in the US. Many pharmacists are unfamiliar with how to screen patients for MASH and identify those at greatest risk for progression to cirrhosis for further evaluation. In addition, resmetirom is a new drug that was FDA approved on March 14, 2024 for MASH through the accelerated approval pathway. Prior to this approval, there were no FDA approved medications for MASH. Most pharmacists who do not specialize in liver disease may not be familiar with this drug and its place in therapy compared to off-label use of other drugs. Pharmacist knowledge of this disease state will improve patient care by identifying patients with at-risk MASH and recommending treatment to reduce downstream complications of decompensated cirrhosis, hepatocellular carcinoma, and death.
This activity is a recording from a live webinar (on 12/17/2024) and those that claim credit for the live webinar should not claim credit for this activity.
CE Credit: 0.5 Contact Hours
Universal Activity Number (UAN): 0025-0000-24-103-H01-P
Activity Type: Knowledge
Launch Date: 12/17/2024
Expiration Date: 12/17/2025
Course Number: HTIP_2024_12_17_Hu
Target Audience: Pharmacists
Course Details (Activity Announcement): View File (HTIP_2024_12_17_Hu Activity Announcement)
Presenter:
Amy Hu, PharmD
PGY-2 Ambulatory Care Pharmacy Resident
University of Maryland
Dr. Hu, faculty for this activity, was employed as an employee with Humana. All financial relationships for Dr. Hu have been mitigated. Dr. Hynika, mentor for this activity, is employed as a consultant with LexiComp. She previously served as a speaker for a free CE activity with PharmCon. All financial relationships for Dr. Hynika have been mitigated.The planners for this activity have no financial relationships to disclose.
The University of Maryland School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Learning Objectives
At the end of this activity, the participant should be able to:
- Explain the mechanism of how liver steatosis, lobular inflammation, and hepatocellular ballooning contribute to liver damage and complications.
- Describe the impact of resmetirom on MASH resolution and reduction in fibrosis staging in clinical trials.
Instructor
Amy Hu, PharmD
PGY-2 Ambulatory Care Pharmacy Resident
University of Maryland
Dr. Hu, faculty for this activity, was employed as an employee with Humana. All financial relationships for Dr. Hu have been mitigated. Dr. Hynika, mentor for this activity, is employed as a consultant with LexiComp. She previously served as a speaker for a free CE activity with PharmCon. All financial relationships for Dr. Hynika have been mitigated.The planners for this activity have no financial relationships to disclose.
Technology Requirements
Unless otherwise noted in the course materials, the following are required to access online courses: A computer or mobile device with a stable internet connection and the ability to view and update Microsoft Word® and PowerPoint® documents.
| Supported Internet Browsers |
Windows
- Internet Explorer version 11 and above
- Chrome 43 and above
- Firefox 4.0 (or later)
MacOS
- Safari 13 and above
- Chrome 43 and above
|
| Minimum Memory |
8 GB (or more) |
| Minimum Storage |
6 GB (or more) |
| Minimum Processor |
PC: 2 GHz or faster Intel processor
MacOS: Multi-core Intel processor |
| Minimum Internet Speeds |
High speed internet connection |
| Other |
Participants must be able to play audio (either through speakers or headphones) as well as ability to open PDF files and view and edit Word, and PPT documents. |
Successful completion requires the participant to complete all activity components including the audiovisual presentations, active leanring, and activity evaluation. Learners must complete the activity evaluation in order to receive CE credit. A link to the activity evaluation will be available once a learner has successfully completed all other course segments.
Privacy and Confidentiality:
The University of Maryland School of Pharmacy is committed to protecting the privacy of our learners. All enrollees are protected under The Family Educational Rights and Privacy Act (20 U.S.C. § 1232g; 34 CFR Part 99) (FERPA). The UMB Policy on Confidentiality and Disclosure of Student Records can be found at: https://www.umaryland.edu/policies-and-procedures/library/academic-affairs/policies/iii-630a.php.
In order to submit your continuing education credit to a professional accrediting body, we must collect personal information including, but not limited to, name, NABP ID, and date of birth. When you request continuing education credits, certain personal information will be provided to the professional certifying entity in order to issue Certificates of Credit.
Copyright: Resources are provided for the educational benefit of our learners and are not for distribution. All information and materials provided are the property of and have been prepared by the University of Maryland Baltimore or have been granted permission for use by the copyright owner. No portion of this module may be reproduced or transmitted without written permission. All rights reserved.
Refund Policy
- A refund, less a $5 administration fee (for each course), will be made if cancellations are requested within 15 days of purchase. Other restrictions may apply.
- Refund requests must be submitted in writing to CEHelp@rx.umaryland.edu.
- Refunds are not available in the following circumstances:
- A learner has logged into a course or series;
- Has launched course materials;
- Course materials have been shipped; or
- Request is made after 15 days of the ordering date.
Course registrations are non-transferrable.
Questions? Review the Frequently Asked Questions page. Can't find what you are looking for? Contact Customer Service at CEHelp@rx.umaryland.edu or 410-706-3381.
